Stock Seesawing Amidst Rampant Activity: Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical Industries the world's biggest generic drugmaker and Israel's largest company is seen in Jerusalem

Teva Pharmaceutical Industries Limited - TEVA - Stock Price Today - Zacks - Zacks Investment Research

They now have a $35.00 target price on the stock.

Other equities research analysts have also issued research reports about the company. Guggenheim Capital LLC increased its position in Teva Pharmaceutical Industries by 1.1% in the fourth quarter. SOL Capital Management CO raised its stake in shares of Teva Pharmaceutical Industries by 10.1% in the first quarter. Analysts set a 12-month price target of $23.81 a share. On Wednesday, January 4 the stock rating was maintained by Maxim Group with "Buy". The legal version of this piece of content can be viewed at https://weekherald.com/2017/08/04/teva-pharmaceutical-industries-limited-teva-cut-to-market-perform-at-sanford-c-bernstein.html. The company has a market capitalization of $21.09 billion, a P/E ratio of 266.1423 and a beta of 0.46. The U.S. firm got its 10 percent holding in Teva as part of the payment for the generics unit, and was required to hold the shares for a 12-month period that ended this week.

Teva Pharmaceutical Industries Ltd.'s shares plunged Thursday after the company posted disappointing second-quarter results, cut its full-year outlook and slashed its dividend, blaming the rapid deterioration of its all-important US generic-drug business. The return on equity ratio or ROE stands at 4 percent while most common profitability ratio return on investment (ROI) was 3.6 percent.

Allergan expects full-year earnings in the range of $16.05 to $16.45 per share, with revenue in the range of $15.85 billion to $16.05 billion. Company shares were recently noted -17.80% off of the 50-day high and -0.44% away from the 50-day low.

Teva Pharmaceutical Industries Limited is a pharmaceutical company.

At the moment 26 analysts are watching Teva Pharmaceutical Industries Limited (NASDAQ:TEVA), 4 rate it "Buy", 6 "Outperform", 16 "Underperform", 0 "Sell", while 0 "Hold". If you are reading this piece of content on another domain, it was copied illegally and republished in violation of global trademark & copyright laws. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of USA and worldwide trademark & copyright legislation.

TRADEMARK VIOLATION WARNING: "Maxim Group Reaffirms "Hold" Rating for Teva Pharmaceutical Industries Limited (NYSE:TEVA)" was first published by Transcript Daily and is owned by of Transcript Daily.

Recent session action on shares of Newell Brands Inc.

Teva also cut its quarterly investor payout, decreasing its dividend payment by 75 percent - now at $0.085, which is about a 1.1 percent annual yield.

The number of shares changed hands in the stock is good, indicating the interest and low risk associated with it. Bank Hapoalim BM now owns 11,673 shares of the company's stock valued at $375,000 after buying an additional 980 shares during the period. Finally, Berson & Corrado Investment Advisors LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter worth $1,072,000. Moreover, Daruma Capital Management Llc has 2.81% invested in the company for 1.04 million shares. The Petach Tikva, Israel-based company said its profit may fall to as low as $4.30 a share for the year. Renaissance Technologies LLC now owns 4,817,763 shares of the company's stock valued at $154,602,000 after buying an additional 2,651,900 shares in the last quarter. Institutional investors own 56.20% of the company's stock.

Teva has been in hot water since February, when former CEO Erez Vigodman stepped down suddenly at what was already an unsteady time for the company. "We have made important progress and it has been positive so far", he said, also deflecting questions from analysts on the prospects of splitting the company into two - generics and specialty drugs.

Latest News